Striatal delta opioid receptor binding in experimental models of Parkinson's disease and dyskinesia.
Enhanced delta opioid receptor transmission may represent an endogenous compensatory mechanism in parkinsonism to reduce the activity of the indirect striatopallidal pathway following dopamine depletion. Furthermore, increased delta opioid receptor transmission may be causative in the production of dyskinesia following repeated dopaminergic treatment in Parkinson's disease. The present study employed radioligand receptor autoradiography, using [3H]naltrindole, a ligand selective for the delta opioid receptor, to assess delta opioid receptor binding sites in forebrain regions of reserpine-treated rats, and in parkinsonian nondyskinetic, and dyskinetic MPTP-lesioned macaques. In reserpine-treated animals, specific delta opioid binding was increased in premotor cortex (+30%), sensorimotor striatum (+20%), and associative striatum (+17%) rostrally, but was not changed in caudal forebrain. In contrast, delta opioid receptor binding was not significantly altered at any region analyzed, in either nondyskinetic or dyskinetic, MPTP-lesioned macaques, compared to normal. These results suggest that transient changes in delta opioid receptor binding may occur in motor circuits following acute dopamine depletion. However, in the more chronic MPTP-lesioned macaque model, simple changes in delta opioid receptor number or affinity are unlikely to contribute to mechanisms for abnormal opioid transmission in Parkinson's disease and dyskinesia.
Hallett
Penelope J
PJ
MassGeneral Institute for Neurodegenerative Disease, Massachusetts General Hopital, Charlestown, Massachusetts 02478, USA. phallett@partners.org
Brotchie
J M
JM
D015632:1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine / Q000494:pharmacology; D000704:Analysis of Variance; D000818:Animals; D003342:Corpus Striatum / Q000187:drug effects / Q000378:metabolism*; D004195:Disease Models, Animal; D050483:Dopamine Plasma Membrane Transport Proteins / Q000378:metabolism; D020820:Dyskinesias / Q000209:etiology / Q000473:pathology*; D008253:Macaca mulatta; D008297:Male; D009271:Naltrexone / Q000031:analogs & derivatives / Q000493:pharmacokinetics; D009292:Narcotic Antagonists / Q000493:pharmacokinetics; D010300:Parkinson Disease / Q000209:etiology / Q000473:pathology*; D016548:Prosencephalon / Q000187:drug effects / Q000378:metabolism; D011869:Radioligand Assay / Q000379:methods; D051381:Rats; D017207:Rats, Sprague-Dawley; D017465:Receptors, Opioid, delta / Q000378:metabolism*; D012110:Reserpine / Q000494:pharmacology; D014316:Tritium / Q000493:pharmacokinetics
D050483:Dopamine Plasma Membrane Transport Proteins; D009292:Narcotic Antagonists; D017465:Receptors, Opioid, delta; D014316:Tritium; D009271:Naltrexone; D012110:Reserpine; D015632:1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; C055382:naltrindole